Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Mirjana %C5%BDumer-Pregelj) .

1 - 10 / 44
First pagePrevious page12345Next pageLast page
1.
The role of PET-CT in radiotherapy planning of solid tumours
Staša Jelerčič, Mirjana Rajer, 2015, review article

Abstract: PET-CT is becoming more and more important in various aspects of oncology. Until recently it was used mainly as part of diagnostic procedures and for evaluation of treatment results. With development of personalized radiotherapy, volumetric and radiobiological characteristics of individual tumour have become integrated in the multistep radiotherapy (RT) planning process. Standard anatomical imaging used to select and delineate RT target volumes can be enriched by the information on tumour biology gained by PET-CT. In this review we explore the current and possible future role of PET-CT in radiotherapy treatment planning. After general explanation, we assess its role in radiotherapy of those solid tumours for which PET-CT is being used most. Conclusions. In the nearby future PET-CT will be an integral part of the most radiotherapy treatment planning procedures in an every-day clinical practice. Apart from a clear role in radiation planning of lung cancer, with forthcoming clinical trials, we will get more evidence of the optimal use of PET-CT in radiotherapy planning of other solid tumours.
Keywords: positron emission therapy, radiotherapy, radiotherapy planning, tumour biology
Published in DiRROS: 16.04.2024; Views: 44; Downloads: 6
.pdf Full text (1,25 MB)

2.
Intercalated chemotherapy and erlotinib for advanced NSCLC : high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Matjaž Zwitter, Karmen Stanič, Mirjana Rajer, Izidor Kern, Martina Vrankar, Natalija Edelbaher, Viljem Kovač, 2014, original scientific article

Abstract: Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC). Patients and methods. Eligible patients were treatment-naive with stage IIIB or IV NSCLC. In addition, inclusion was limited to never-smokers or light smokers or, after 2010, to patients with activating epidermal growth-factor receptor (EGFR) mutations. Treatment started with 3-weekly cycles of gemcitabine and cisplatin on days 1, 2 and 4 and erlotinib on days 5 to 15. After 4 to 6 cycles, patients continued with erlotinib maintenance. Results. Fifty-three patients were recruited into the trial: 24 prior to 2010 (of whom 9 were later found to be positive for EGFR mutations), and 29 EGFR mutation-positive patients recruited later. Unfavourable prognostic factors included stage IV disease (51 patients - 96%), performance status 2%3 (11 patients - 21%) and brain metastases (15 patients - 28%). Grade 4 toxicity included 2 cases of neutropenia and 4 thrombo-embolic events. The 15 EGFR negative patients had 33% objective response rate, median progression-free survival (PFS) 6.0 months and median survival 7.6 months. Among 38 EGFR positive patients, complete response (CR) or partial response (PR) were seen in 16 (42.1%) and 17 (44.7%) cases, respectively. PET-CT scanning was performed in 30 patients and confirmed CR and PR in 16 (53.3%) and 9 (30.0%) cases, respectively. Median PFS for EGFR mutated patients was 21.2 months and median survival was 32.5 months. Conclusions. While patients with EGFR negative tumors do not benefit from addition of erlotinib, the intercalated schedule appears most promising for those with EGFR activating mutations.
Keywords: non-small cell lung cancer, EGFR activating mutations, gemicitabine, erlotinib
Published in DiRROS: 11.04.2024; Views: 82; Downloads: 20
.pdf Full text (590,54 KB)

3.
Malignant spinal cord compression
Mirjana Rajer, Viljem Kovač, 2008, review article

Abstract: Malignant spinal cord compression (MSCC) is a common and debilitating neurological complication of cancer. Because of the rapid progression of the neurological dysfunction, it is considered a medical emergency that demands a prompt diagnosis and treatment. Almost all of the MSCC are caused by an epidural compression from a tumour or a bony fragment from the collapsed vertebra affected by the metastasis. The most common of the tumours that metastasize to the spinal cord are breast and lung cancer, followed by lymphoma, myeloma, prostate cancer and sarcoma. Conclusions. The most common symptom of MSCC is pain, followed by muscular weakness and autonomic dysfunction. MRI provides the best information regarding MSCC, so all patientsshould have a MRI as soon as possible. If the MRI is contraindicated, patients should have the CT scan done. All patients with newly diagnosed MSCC should receive corticosteroids immediately, even before the definitive diagnosis is made. Other treatment options are surgery with postoperative radiotherapy, radiotherapy only, specific medical therapies according to the tumour type and symptomatic therapy, (mainly opiates). The decision of treatment modalities should be made according to the NOMS (neurological, oncological, mechanical and systemic) principles. In spite of the advances, the treatment is still palliative and many patients with MSCC have a poor prognosis and a short survival.
Published in DiRROS: 07.03.2024; Views: 109; Downloads: 24
.pdf Full text (152,89 KB)

4.
Kidney cancer
Mirjana Rajer, 2007, professional article

Published in DiRROS: 20.02.2024; Views: 104; Downloads: 27
.pdf Full text (213,38 KB)

5.
Basic Clinical Radiobiology Course Ljubljana (Slovenia), 21.-25. May 2006 : view from local participant
Mirjana Rajer, 2007, other component parts

Published in DiRROS: 20.02.2024; Views: 98; Downloads: 27
.pdf Full text (66,97 KB)

6.
Locoregional control and survival after breast conserving therapy
Mirjana Rajer, Elga Majdič, 2006, original scientific article

Published in DiRROS: 15.02.2024; Views: 108; Downloads: 30
.pdf Full text (631,72 KB)

7.
Quantitative analysis of fine needle aspiration biopsy samples
Mirjana Rajer, Marko Kmet, 2005, original scientific article

Abstract: The fine needle aspiration biopsy (FNAB) is one of the methods used in tumour evaluation. Since a certain number of tumour cells are needed for a complete diagnostic algorithem, we wanted to test how many cells remain in the needle and syringe after routine stains have been made and which factors influence this number. The remaining cells are used in ancillary diagnostic procedures. Material and methods. One hundred fifty two FNAB samples of tumours of the breast, thyroid and lymph nodes were included in our study. We counted the cells which were left in the needle and the syringe after the standard smears had been made. Buerker-Tuerks chamber was used for this purpose. Results. The number of cells depended on the organ from which the cells had been aspirated,on the type of tumour and, in the case of breast cancer, also on thelevel of experience of the FNAB performer. The percentage of samples with too few cells for all modern diagnostic methods (<5x105) is lowest in FNAB of lymph nodes (4.9%), followed by breast (16.7%) and thyroid (18%). Conclusions.We concluded that FNAB in the majority of cases grants a sufficient number of cells for the standard microscopic evaluation and also ancillary diagnostic procedures.
Published in DiRROS: 14.02.2024; Views: 123; Downloads: 26
.pdf Full text (104,56 KB)

8.
Indium-111-DTPA-octreotide scintigraphy in patients with carcinoid tumor
Stanko Težak, Rajko Ostojić, Zdravko Perković, Nadan Rustemović, Nikica Car, Branko Papa, Mirjana Poropat, Damir Dodig, 1999, original scientific article

Abstract: Background. The aim of the study was the evaluation of clinical utility and comparison of 111 In-DTPA- octreotide receptor scintigraphy (SRS) with conventional imaging modalities (CIM) in the detection of carcinoid tumor. Patients and methods. Fourteen patients with pathohistologically proven diagnosis of carcinoid tumor and one patient with clinical suspicion of carcinoid tumor were investigated by SRS. SRS was performed for localization of primary tumor, recurrence or estimation of spread of the disease after CIM had been completed. Whole body scans and single photon emission computed tomography (SPECT) were acquired 6 and 24 h after the application of radiopharmaceutical. The intensity of nonspecific radiopharmaceutical uptake in the bowel was assessed semiquantitatively by a score using whole body scans. Results. The evaluation was done for patients and for tumor sites. The sensitivity, specificity, and positive and negative predictive values for patient evaluation were 89 %,100 %,100 % and 80 %, respectively for both CIM and SRS, whereas for tumor sites, these parameters were 69 % 100 %,100 % and 82 % for CIM, and 88%,100%,100% and 92 % for SRS. Intensity score of nonspecific 111In-octreotide bowel accumulation was 0.92 and 2.01 for 6 and 24h scans respectively (p < 0.01). Conclusion. 111In-octreotide scintigraphy should be included in the diagnostic algorithm for the patients with clinical suspicion of carcinoid and for the assessment of patients with proven carcinoid tumor.
Published in DiRROS: 22.01.2024; Views: 154; Downloads: 32
.pdf Full text (554,71 KB)

9.
10.
Delovnoterapevtska obravnava uporabnika v paliativni oskrbi
Katarina Galof, Katarina Hekič, Mirjana Klajnšek, 2023, published scientific conference contribution abstract

Keywords: delovna terapija, paliativna oskrba, bivalno okolje
Published in DiRROS: 23.11.2023; Views: 161; Downloads: 71
.pdf Full text (239,01 KB)

Search done in 0.23 sec.
Back to top